Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Patria
- Development stage
- Phase 3
- Lead developer
- Avi-Mex
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
Patria is a recombinant viral vector vaccine developed for the prevention of COVID-19. It utilizes a live-attenuated Newcastle Disease Virus (NDV) vector that has been engineered to express a stabilized version of the SARS-CoV-2 spike protein, known as HexaPro (HXP-S). This stabilized antigen was developed by researchers at the University of Texas at Austin and the Icahn School of Medicine at Mount Sinai to enhance protein expression and immunogenicity. The vaccine is designed for both intramuscular and intranasal administration, with the latter intended to stimulate mucosal immunity in the respiratory tract. Developed by Laboratorio Avi-Mex in collaboration with the Mexican government and international academic partners, Patria was designed to be a cost-effective and scalable vaccine solution, leveraging existing influenza vaccine manufacturing infrastructure.
- Brand names
- Patria
- Other names
- AVX-COVID-12AVX-COVID12AVX-COVID 12
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on Patria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Patria.